126 related articles for article (PubMed ID: 33733338)
1. Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses.
Schalkwijk S; Sahota T; Verheijen RB; Harmer AR; Ahmed GF
AAPS J; 2021 Mar; 23(3):46. PubMed ID: 33733338
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
Sahota T; Dota CD; Vik T; Yan W; Verheijen RB; Walker S; Li Y; Goldwater R; Ghiorghiu D; Mellemgaard A; Ahmed GF
Clin Pharmacol Drug Dev; 2021 May; 10(5):521-534. PubMed ID: 33400845
[TBL] [Abstract][Full Text] [Related]
3. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
5. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Dubourg J; Perrimond-Dauchy S; Felices M; Bolze S; Voiriot P; Fouqueray P
Eur J Clin Pharmacol; 2020 Oct; 76(10):1393-1400. PubMed ID: 32556539
[TBL] [Abstract][Full Text] [Related]
6. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
[TBL] [Abstract][Full Text] [Related]
7. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
[TBL] [Abstract][Full Text] [Related]
8. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
[TBL] [Abstract][Full Text] [Related]
9. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
[TBL] [Abstract][Full Text] [Related]
10. PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
Henrich A; Juif PE; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):213-224. PubMed ID: 33389549
[TBL] [Abstract][Full Text] [Related]
11. PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration.
Jaminion F; Bentley D; Wang K; Wandel C; Derks M; Diack C
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):447-459. PubMed ID: 32572738
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Gan HK; Millward M; Hua Y; Qi C; Sai Y; Su W; Wang J; Zhang L; Frigault MM; Morgan S; Yang L; Lickliter JD
Clin Cancer Res; 2019 Aug; 25(16):4924-4932. PubMed ID: 30952639
[TBL] [Abstract][Full Text] [Related]
13. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
14. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
Charbit B; Alvarez JC; Dasque E; Abe E; Démolis JL; Funck-Brentano C
Anesthesiology; 2008 Aug; 109(2):206-12. PubMed ID: 18648229
[TBL] [Abstract][Full Text] [Related]
15. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
17. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers.
Shumaker RC; Zhou M; Ren M; Fan J; Martinez G; Aluri J; Darpo B
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1109-17. PubMed ID: 24658627
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.
Funck-Brentano C; Felices M; Le Fur N; Dubourdieu C; Desché P; Vanhoutte F; Voiriot P
Br J Clin Pharmacol; 2020 Nov; 86(11):2174-2181. PubMed ID: 32302009
[TBL] [Abstract][Full Text] [Related]
20. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
